Tetrahydrocannabivarin is a propyl analogue of tetrahydrocannabinol that acts as a Cannabinoid receptor type 1 antagonist and a partial agonist of Cannabinoid receptor type 2. Beyond the endocannabinoid system, Tetrahydrocannabivarin has also been reported to activate 5HT1A receptors to produce an antipsychotic effect that has therapeutic potential for ameliorating some of the negative, cognitive and positive symptoms of schizophrenia. Animal studies have shown that, like rimonabant, Tetrahydrocannabivarin reduces weight gain and food consumption in non-fasted mice but does not increase activity in the brain regions involved in emotion regulation. In another study, involving diet-induced obese mice, oral Tetrahydrocannabivarin reduced body fat content, increased energy expenditure, and reduced fasting insulin and 30-min insulin response to oral glucose tolerance test. In clinical trials THCV significantly decreased fasting plasma glucose and improved pancreatic β-cell function.